Company: INDP
Filing Date: 2025-03-13
Form Type: 10-K
Source: 0001493152-25-010136
Chunk: 100

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-03-13
Form: 10-K
Item: Item 1
Chunk 100
---
.2)%
  
    Loss from operations 
     (15,365,751) 
     (16,378,474) 
     1,012,723  
     (6.2)%
  
    Other income, net 
     343,724  
     955,003  
     (611,279) 
     (64.0)%
  
    Net loss 
    $(15,022,027) 
    $(15,423,471) 
    $401,444  
     (2.6)%
  
    Net loss attributable to common stockholders per share, basic and diluted 
    $(1.61) 
    $(1.83) 
    $0.22  
     (12.0)%
  
    Weighted average number of shares used in calculating net loss per share, basic and diluted 
     9,355,710  
     8,401,047  

65

Research
and Development Expenses

Our
research and development expenses for the year ended December 31, 2024 amounted to approximately $7.2 million, a decrease of approximately
$0.4 million, or approximately 4.9%, compared with approximately $7.6 million for the year ended December 31, 2023. This decrease was
attributable primarily to a decrease of approximately $1.3 million for the development of our manufacturing processes of Decoy20 that
were mainly conducted in 2023 and was offset by an increase of approximately $0.9 million in costs associated with our Phase 1 clinical trial.

General
and Administrative Expenses

Our
general and administrative expenses for the year ended December 31, 2024 amounted to approximately $8.1 million, a decrease of approximately
$0.7 million, or approximately 7.3%, compared with approximately $8.8 million for the year ended December 31, 2023. This decrease was
attributable primarily to a decrease of approximately $1.3 million in legal fees, recruitment costs, payroll and related expenses, franchise
tax, and directors’ and officers’ insurance expenses, and was offset by an increase of approximately $0.6 million in investor
relations and business development expenses.

Other
Income

During
the year ended December 31, 2024, our other income, net was approximately $0.3 million, which represented a decrease of approximately
$0.